These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17893640)

  • 1. [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis].
    Farnier M; Bonnet F; Bruckert E; Ferrières J; Paillard F;
    Arch Mal Coeur Vaiss; 2007; 100(6-7):569-81. PubMed ID: 17893640
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia].
    Kłosiewicz-Latoszek L; Cybulska B
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II76-80. PubMed ID: 19813341
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
    Balbisi EA
    Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Statin plus niacin or ezetimibe? What combination for which patients?].
    Parhofer K
    MMW Fortschr Med; 2009 Dec; 151(49-50):16. PubMed ID: 20085070
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical inquiries. What are effective medication combinations for dyslipidemia?
    Saseen J; Tweed E; Crawford P
    J Fam Pract; 2006 Jan; 55(1):70-2. PubMed ID: 16388773
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.
    Lal SM; Katyal A
    Mo Med; 2002; 99(10):580-4. PubMed ID: 12534147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia treatment: current considerations and unmet needs.
    Malik S; Kashyap ML
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):121-34. PubMed ID: 15030302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
    Klose G
    MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations.
    Lavie CJ
    Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):29-33. PubMed ID: 15133427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of lipid-lowering drug therapy in children and adolescents.
    Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for lipids.
    Treat Guidel Med Lett; 2005 Mar; 3(31):15-22. PubMed ID: 15726011
    [No Abstract]   [Full Text] [Related]  

  • 13. Choice of lipid-lowering drugs.
    Med Lett Drugs Ther; 1998 Dec; 40(1042):117-22. PubMed ID: 9884672
    [No Abstract]   [Full Text] [Related]  

  • 14. Intensive lipid-lowering therapy: obvious benefits, possible risks.
    Zimlichman E; Szyper-Kravitz M; Katz U; Shoenfeld Y
    Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117
    [No Abstract]   [Full Text] [Related]  

  • 15. First-line therapies for lowering triglyceride levels.
    Raghavan VA
    Am Fam Physician; 2008 Feb; 77(4):416; author reply 417-8. PubMed ID: 18326158
    [No Abstract]   [Full Text] [Related]  

  • 16. Choice of lipid-lowering drugs.
    Med Lett Drugs Ther; 1996 Aug; 38(980):67-70. PubMed ID: 8692076
    [No Abstract]   [Full Text] [Related]  

  • 17. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial).
    Farmer JA
    Curr Atheroscler Rep; 2009 Mar; 11(2):82-3. PubMed ID: 19228479
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
    Gadarla M; Kearns AK; Thompson PD
    Am J Cardiol; 2008 Jun; 101(12):1747-8. PubMed ID: 18549851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving cholesterol goals. Current and future drug therapies.
    Jones PH
    Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-intensity statin monotherapy versus moderate-intensity statin plus ezetimibe therapy: effects on vascular biomarkers.
    Ferreira CE; França CN; Izar MC; Camargo LM; Roman RM; Fonseca FA
    Int J Cardiol; 2015 Feb; 180():78-9. PubMed ID: 25438220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.